SOURCE: Critical Outcome Technologies Inc. (COTI)

Critical Outcome Technologies Inc. (COTI)

March 22, 2016 14:41 ET

Critical Outcome Technologies Provides Market Update

LONDON, ON--(Marketwired - March 22, 2016) - Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") announced at the request of IIROC that its continuous disclosure responsibilities are up to date and all material transactions and news in this regard have been disclosed to the market.

"We are very pleased that the market is starting to recognize the value that our development programs can bring," said Dr. Wayne Danter, President & Chief Executive Officer. "Over the past month we have announced a number of important milestones including the commencement of patient dosing in our Phase 1 trial for COTI-2 in gynecologic cancers targeting p53 mutations, the release of our ROSALIND machine learning platform that engages oncologists in developing this tool for improving personalized cancer treatment, and additional financing from warrant exercises that provides support for operations, particularly the Phase 1 trial into 2017."

About Critical Outcome Technologies Inc. (COTI) 

COTI is a clinical stage biopharmaceutical company advancing the treatment of cancer through targeted therapeutics. The Company's lead compound, COTI-2, has a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. The initial therapeutic indication is in gynecologic cancers, which includes ovarian, cervical, and endometrial cancers; a Phase 1 clinical trial began at MD Anderson Cancer Center in December 2015. The Company has secured orphan drug status for the ovarian indication in the U.S. and is planning additional studies in other cancer indications such as head and neck, Li-Fraumeni Syndrome, and acute myelogenous leukemia, based upon more than ten animal xenograft models showing both single and combination agent activity of COTI-2 with other leading cancer drugs. Preclinical data provides evidence to suggest a potentially dramatic change in the treatment of cancers with mutations of the p53 gene.

Follow @CriticalOutcome on Twitter at

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information